Inclusion Criteria:

          -  ≥ 18 years of age.

          -  Histologically confirmed diagnosis of glioblastoma (after initial tumor resection or
             biopsy) with radiographic evidence of recurrent tumor per RANO criteria.

          -  Phase Ib: Documented evidence of PTEN mutations, homozygous deletion of PTEN or PTEN
             negative (H Score <10) by IHC confirmed by local or central assessment.

          -  Phase II: Documented evidence of c-Met amplification (GCN>5) (fusion transcripts or
             mutant c-Met may be eligible after discussion with Novartis) or PTEN mutations,
             homozygous deletion of PTEN or PTEN negative (H Score <10) by central assessment.

          -  Must have received the following treatment for glioblastoma:

             •Prior treatment with radiotherapy and temozolomide; Note: A maximum of two prior
             chemotherapy/antibody regimens (including bevacizumab or other direct VEFG/VEGFR
             inhibitors) for recurrent disease are permitted.

          -  Representative archival tumor sample from glioblastoma (formalin-fixed paraffine
             embedded tissue) must be available.

          -  ECOG performance status ≤ 2.

          -  Able to swallow and retain oral medication.

          -  Patients in the surgical arm only: patients with recurrent glioblastoma must be
             eligible for surgical resection as deemed by the site Investigator.

        Exclusion Criteria:

          -  Prior or current treatment with a c-MET inhibitor or HGF-targeting therapy

          -  Prior treatment with a PI3K and/or mTOR inhibitors for glioblastoma or for
             pre-existing neoplasm transformed to glioblastoma (applicable for combination
             treatment arm only)

          -  Received radiation (including therapeutic radioisotopes such as strontium 89) therapy
             ≤ 3 months prior to the first dose of study treatment and have not recovered from side
             effects of such therapy (≤ Grade 1) prior to the first dose of study treatment, except
             for alopecia.

          -  Receiving treatment with medications that are known strong inhibitors or inducers of
             CYP3A, and cannot be discontinued 7 days prior to the start of the treatment and
             during the course of the study.

          -  Receiving treatment with medications that are known CYP3A, CYP1A2, CYP2C8, CYP2C9 or
             CYP2C19 substrates with narrow therapeutic index, and cannot be discontinued during
             the course of the study.

          -  Receiving treatment with long acting proton pump inhibitors, and cannot be
             discontinued 3 days prior to the start of INC280 treatment and during the course of
             the study.

          -  Currently receiving warfarin or other coumadin-derived anticoagulants for treatment,
             prophylaxis or otherwise.

          -  Currently receiving increasing or chronic treatment ( > 5 days) with corticosteroids
             (e.g. dexamethasone > 4 mg/day or other corticosteroids equivalent dose) or another
             immunosuppressive agent.

          -  History of acute or chronic pancreatitis or any risk factors that may increase the
             risk of pancreatitis.

          -  Active cardiac disease or a history of cardiac dysfunction.

          -  Impairment of gastrointestinal (GI) function or GI disease that might significantly
             alter the absorption of study drug

          -  Medically documented history of or active major depressive episode, bipolar disorder
             (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt
             or ideation, or homicidal ideation (e.g. risk of doing harm to self or others), or
             patients with active severe personality disorders (defined according to DSM- IV).

          -  Anxiety ≥ CTCAE grade 3

          -  Any of the following baseline laboratory values:

               -  Hemoglobin < 9 g/dL

               -  Platelet count < 75 x 109/L

               -  Absolute neutrophil count (ANC) < 1.0 x 109/L

               -  INR > 1.5

               -  Serum lipase > normal limits for the institution

               -  Asymptomatic serum amylase > grade 2

               -  Potassium, magnesium, and calcium (corrected for albumin) > normal limits for the
                  institution

               -  Total bilirubin > 1.5 x ULN

               -  Serum creatinine >1.5 x ULN or creatinine clearance ≤ 45 mL/min

               -  Alanine aminotransferase (AST) or aspartate aminotransferase (ALT) > 3.0 x ULN
                  (or < 5.0 x ULN if liver metastases are present)

               -  Fasting plasma glucose > 120mg/dL or > 6.7 mmol/L

               -  HbA1c > 8%.